பத்திரிகை அறிக்கை
டீல்
டீல் மதிப்பு₹1495 கோடி
டீல் vs வணிகம்order = 1.8x TTM revenue (spread over 10 years, ~18.2% of TTM revenue annually)
சொந்த வருவாயுடன் ஒப்பிடும் அளவு1.80×
செயல்படுத்தும் காலம்10.0 ஆண்டு
அடிப்படை தரம்C
AI முன்கணிப்புகள்
வருவாய் உயர்வு (முதல் ஆண்டு / நிலையான)9.1% / 18.2%
EPS உயர்வு150.0%
அப்சைடு பேஸ் / புல் / பேர்45.0% / 110.0% / -30.0%
கால எல்லை24-36 மாதங்கள்
உண்மையான சந்தைப் பதிவு
நுழைவு — அடுத்த நாள் தொடக்கம்(08 ஜூலை 2026)₹970.05
சமீபத்திய முடிவு விலை(12 நவ. 2026)₹857.8
தொடங்கியதிலிருந்து வருமானம்-11.6%
α vs Smallcap 250-13.8%
α vs சொந்தத் துறை-14.9% (மருந்துகள் - இந்திய - மொத்த மருந்துகள் & ஃபார்முலேஷன்ஸ் இடைநிலை +1.1%, 85 முதிர்ந்த தேர்வுகளின் அடிப்படையில்)
நேர்மறைகள்
- First Indian-originated NCE (Exblifep) to receive USFDA and EMA approvals, validating R&D capability
- High-value finished dosage form supply agreement rather than low-margin API supply
- Strong local partner in Russia (Pharmasyntez) with a massive hospital procurement network
- Substantial operating leverage potential as sterile unit capacity utilization is already high and expanding
அபாயங்கள்
- Extremely high trailing valuation (P/E of 230.6x) leaves zero room for execution delays
- Regulatory approval risk with the Russian Ministry of Health before commercialization can begin
- High product concentration (71% of FY24 revenue from just two products) and high dependency on Chinese imports
- Historically weak financial profile (ROCE of 4.0%, volatile quarterly margins) post-CIRP resolution
முழு AI சுருக்கம்
1. ராம்ப்-அவேர் தாக்கக் கணக்கீடு
- Deal Value & Duration: USD 178 million (approx. ’1,477 Cr) over a 10-year period. This translates to an annualized revenue opportunity of ’147.7 Cr.
- Ramp-up Assumptions: Year 1 is highly unlikely to see full commercialization due to pending regulatory approval by the Russian Ministry of Health. We assume a 50% ramp-up in Year 1 post-approval (’73.8 Cr) and 100% steady-state run-rate (’147.7 Cr) from Year 2 onwards.
- Revenue Uplift: Year 1 revenue uplift is estimated at 9.1% of TTM revenue (’812 Cr). Steady-state annual revenue uplift is 18.2%.
- Margin & EPS Impact: Orchid's current consolidated TTM PAT is depressed at ’22 Cr (OPM 5.1%) due to inventory setbacks and pricing pressures. However, finished dosage NCE supply typically commands higher EBITDA margins (estimated at 25-30%). At a conservative 20% net margin on this contract, steady-state incremental PAT would be ’29.5 Cr. This represents a >130% increase over TTM PAT, translating to an EPS uplift of ~150% (incremental EPS of ~’5.40 on the current base of ’4.01).
2. தொழில்துறை மூலதனத் தீவிரம் & எதிர்பார்க்கப்படும் CAGR
- Capital Intensity: Medium. While API manufacturing is capital-intensive, Orchid has already expanded its sterile unit capacity to 200-225 MT. The incremental capex for this specific deal is minimal as they are leveraging existing/expanded capacities.
- Industry CAGR: The Indian bulk drugs and formulations industry is expected to grow at a structural CAGR of 12% over the next decade, driven by global generic adoption and specialized NCE outsourcing.
3. மல்டிபேக்கர் தர மதிப்பீடு
- Financials: Trailing ROCE of 4.0% is weak, reflecting historical distress under CIRP. However, quarterly performance shows a strong recovery in Mar 2026 (PAT of ’24 Cr vs net losses in the preceding two quarters). Debt is manageable at ’185 Cr (D/E of 0.14).
- Promoter & Governance: Promoter holding is stable and high at 69.84% under Dhanuka Laboratories. No major governance red flags are identified.
4. Scenario Analysis (Valuation & Price Targets)
- Base Case (45% Upside): Regulatory approval is received within 9-12 months. Commercialization starts in late FY27. EPS rises to ’9.50. Multiple compresses from the current speculative 230x to a more sustainable but premium 140x, yielding a target price of ~’1,330.
- Bull Case (110% Upside): Rapid Russian approval and faster-than-expected market penetration via Pharmasyntez's hospital network. Operating leverage kicks in, pushing overall OPM past 15%. EPS reaches ’13.00. Premium multiple of 150x is sustained due to NCE success, yielding a target price of ~’1,950.
- Bear Case (-30% Downside): Severe regulatory delays in Russia or pricing caps squeeze margins. The stock de-rates sharply towards peer median multiples (21.2x) due to high initial valuations, partially offset by the floor value of the USFDA/EMA approved NCE. Target price drops to ~’650.
5. தீர்ப்பின் காரணம்
Orchid Pharma is a classic turnaround candidate post-CIRP. The Exblifep licensing deal is highly material, representing 1.8x TTM revenue spread over 10 years. While the trailing valuation is extremely expensive (P/E of 230.6x), the structural shift from low-margin generics to high-margin NCE licensing justifies a premium. Execution risk remains high due to regulatory dependency, placing this in the 'POSSIBLE' multibagger category rather than 'STRONG_CANDIDATE' until consistent quarterly execution is visible.
2026-07-07 நிலவரப்படி பகுப்பாய்வு (விலை ₹924.60) · AI ஆய்வு, முதலீட்டு ஆலோசனை அல்ல.
பின்தொடர்Telegram
